A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs ABY 035 (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms AFFIRM-35
- Sponsors Affibody
- 16 Jul 2019 According to a Affibody media release, trial completion is expected in the first half of 2020.
- 17 Apr 2019 Planned End Date changed from 31 Jul 2019 to 1 Mar 2020.
- 17 Apr 2019 Planned primary completion date changed from 30 Oct 2018 to 29 Jan 2020.